INJECTABLE DRUG DELIVERY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Injectables offer maximum bioavailability of drugs towards the intended site of action and avoid the first pass metabolism. The injectable route is mostly preferred for the drugs which can’t be taken orally or have some stability problems. Unconscious patients or patients having low compliance towards oral tablets or capsules can be preferred for the injectable drug delivery therapy.

Market Dynamics

Increasing prevalence of chronic diseases such as diabetes, cardiac diseases, and anaphylaxis has supported growth of global injectable drug delivery market. According to the Allergy, Asthma & Clinical Immunology, in 2015, around 15 million people suffered from food allergies in the U.K. Similarly, according to the European Academy of Allergy and Clinical Immunology (EAACI), in 2015, around 17 million people suffered from food allergies in the U.K., of which around 3.5 million were children. Increasing awareness regarding safety and concern of needlestick injuries is a major factor driving growth of the injectable drug delivery market. For instance, the WHO recommended the use of safety syringes with sharp injury protection (SIP), in order to prevent needlestick injuries. Similarly, in May 2017, Innovative Neurons LLC announced to commercialize its patented auto retractable multi-needle syringe known as FAST (fast, accessible, safe, and technology) to decrease needlestick injuries. Various market players are focusing on the development and advancement in this space. For instance, ACT-O-VIAL System offered by Pfizer Inc. is a dual-component vial system that allows reconstitution of sterile, injectable medications by pressing on the plastic cap. The facility launch by market players to cater requirements of patients is expected to drive the market growth. For instance, in July 2018, Pfizer, Inc. announced to build sterile injectable pharmaceutical production facilities in the Michigan, U.S.

However, product recalls by the manufacturers is the major factors restraining the market over the forecast period. For instance, in April 2018, Becton Dickson and Company announced a recall of PosiFlush Heaparin Lock Flush Syringe, and Prefilled normal saline syringe, owing to the contamination with Serratia marcescens bacterium.

Key features of the study

• This report provides in-depth analysis of the injectables drug delivery market and provides market size (USD million) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
• It profiles key players in the global injectable drug delivery market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include, Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, Injex Pharma GmbH.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
• The global injectables drug delivery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global injectable drug delivery market

Market Segmentation

• Device Type Insights (Revenue, USD Bn, 2026 - 2033)
  • Prefilled Syringes
  • Auto Injectors
  • Pens
  • Conventional Syringes
  • Cartridges
  • Ampoules
  • Vials
  • Others
• Material Type Insights (Revenue, USD Bn, 2026 - 2033)
  • Glass
  • Plastic
• Usability Insights (Revenue, USD Bn, 2026 - 2033)
  • Disposable
  • Reusable
• Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
  • Intravenous
  • Intramuscular
  • Subcutaneous
• End User Insights (Revenue, USD Bn, 2026 - 2033)
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • North Africa
    • Central Africa
    • South Africa
• Key Players Insights
  • Becton, Dickinson and Company
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Gerresheimer AG
  • Carl-Zeiss-Stiftung
  • Terumo Corporation
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • SHL Group
  • Owen Mumford Limited
  • Injex Pharma GmbH